Search results
Author(s):
Michael C Gibson
Added:
5 years ago
Dr C. Michael Gibson (Beth Israel Deaconess Medical Center, Boston, MA, US) discusses Rivaroxaban 2.5 mg BID combined with DAPT for the prevention of death/MI/stroke - a patient level data meta-analysis of the ATLAS-ACS-2 TIMI-51 and the COMMANDER HF trials
Filmed on site at CRT 2019 by Radcliffe Cardiology
Questions:
1. Why did you conduct this analysis?
2. How was data collected and…
View more
Author(s):
Paul Guedeney
,
Birgit Vogel
,
Roxana Mehran
Added:
3 years ago
Dual antiplatelet therapy (DAPT) including aspirin and a P2Y12 inhibitor is the current gold standard for the treatment and mid-term secondary prevention of acute coronary syndrome (ACS).1–4 However, despite the use of potent P2Y12 inhibitors such as ticagrelor or prasugrel, patients remain at high ischaemic risk after ACS. More specifically, in the prasugrel treatment arm of the TRial to Assess…
View more
Author(s):
Ole De Backer
Added:
4 years ago
Prof Ole De Backer (Rigshospitalet, Copenhagen, DK) provides an update from theGALILEO-4D trial, discussing the comparison ofa Rivaroxaban-Based Strategy With an Antiplatelet-Based Strategy for the Prevention of Subclinical Leaflet Thrombosis in Transcatheter Aortic Valves.
What is the GALILEO-4D study and how is it related to the main GALILEO trial?
What is the design of the study and what…
View more
Author(s):
Stuart J Head
,
Ad JJC Bogers
,
A Pieter Kappetein
Added:
3 years ago
Valvular Heart Surgery
The field of cardiac surgery is urgently in need of new anticoagulant agents. Approximately 300,000 prosthetic valves are implanted yearly, after which lifelong anticoagulation therapy is mandatory as thromboprophylaxis. To date, vitamin K antagonists (VKAs), such as warfarin, remain the only licensed agents to prevent mechanical valve-induced thromboembolic events but have…
View more
Author(s):
Mirvat Alasnag
,
Added:
3 years ago
Dr Mirvat Alasnag (The King Fahd Armed Forces Hospital, Jeddah, KSA) and Dr Connie N Hess (University of Colorado School of Medicine, Aurora, CO, US) discuss the results of the sub-analysis of the VOYAGER PAD Study.
The VOYAGER PAD trial showed that rivaroxaban/aspirin was superior to aspirin at preventing major adverse limb and cardiovascular events.
Dr Hess describes the design of the secondary…
View more
Managing the Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients on Oral…
Author(s):
Darshni Arishta Jhagroe
,
Jurrien M ten Berg
Added:
3 years ago
Article
Author(s):
Andrew Archbold
Added:
3 years ago
Patients who undergo coronary artery stenting require dual antiplatelet therapy (DAPT) in order to reduce their risk of stent thrombosis. Long-term oral anticoagulation (OAC) is indicated for the primary and secondary prevention of thrombotic events in patients with atrial fibrillation (AF), mechanical heart valves, intra-cardiac thrombus, venous thromboembolic disease and some hypercoagulable…
View more
Anticoagulation after TAVI
Author(s):
Antonio Greco
,
Davide Capodanno
Added:
3 years ago
Article
Update on DAPT
Video
Author(s):
Eunice NC Onwordi
,
Amr Gamal
,
Azfar Zaman
Added:
3 years ago
Acute coronary syndromes (ACS) are a major cause of morbidity and mortality. Despite the use of optimal medical therapy and revascularisation there remains a significant risk of vascular events. Registry data indicates a persistent risk even in patients who are event free in the first year following ACS, with as many as 1 in 5 patients suffering a vascular event in the subsequent 3 years.1
The…
View more